CREDO 2 (NCT02760407) and CREDO 3 (NCT02760433) were phase 3 randomised controlled trials, that investigated the efficacy and safety of olokizumab compared to placebo and adalimumab in moderate to severely active rheumatoid arthritis (RA). touchIMMUNOLOGY were delighted to speak with Prof. Vibeke Strand (Stanford University, Palo Alto, CA, USA) to discuss the findings from her analyses looking at patient reported outcomes (PROs) in these studies and the importance of PROs in clinical trials for RA.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstracts ‘Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial.‘ (Abstract number: 0313) and ‘Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial‘ (Abstract number: 0314) were presented at the ACR Convergence, November 10–14, 2022.
- What is the importance of patient reported outcomes in clinical trials in rheumatoid arthritis (RA)? (0:25)
- What is the rationale for the use of olokizumab in the treatment of RA? (1:20)
- What were the aims, design and eligibility criteria of CREDO 2? (2:01)
- What were the findings of the study? (2:48)
- Please could you give us an overview of CREDO 3 and the findings from the study? (4:57)
- On the basis of these findings and recently published data showing noninferiority to adalimumab in terms of ACR 20, where do you see olokizumab eventually sitting in the treatment paradigm for RA? (5:34)
Disclosures: Vibeke Strand discloses consulting for, serving on advisory boards for and receiving honoraria from Abbvie, Alpine Immune Sciences, Alumis, Amgen Corporation, Aria, AstraZeneca, Bayer, Bioventus, Blackrock, BMS, Boehringer Ingelheim, Celltrion, Chemocentryx, Endo, Equillium, Ermium, Genentech / Roche, Gilead, GSK, Horizon, Inmedix, Janssen, Kiniksa, Kypha, Lilly, Merck, MiMedx, Novartis, Omeros, Pfizer, Priovant, Regeneron, Rheos, R-Pharm, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sorrento, Spherix, and Tonix.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatoid Arthritis
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Kim Lauper, ACR 2022: Safety of JAK-inhibitors in rheumatoid arthritis in a real-world population
The JAK inhibitor (JAKi) tofacitinib was associated with an increased risk of serious adverse events compared to TNF-inhibitors in the treatment of rheumatoid arthritis in the ORAL surveillance study (NCT02092467). In this interview, touchIMMUNOLOGY were delighted to speak with Dr. Kim Lauper (Geneva University Hospitals, Genéve, Switzerland) around her study assessing the safety of JAKis […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!